Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany-Reference-Cited by-同舟云学术

Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany

Published:2019-01 Issue:1 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Iftner Thomas¹,Neis Klaus-Joachim²,Castanon Alejandra³⁴,Landy Rebecca³,Holz Barbara¹,Woll-Herrmann Astrid²,Iftner Angelika¹,Staebler Annette⁵,Wallwiener Diethelm⁶,Hann von Weyhern Claus⁵,Neis Felix⁶,Haedicke-Jarboui Juliane¹,Martus Peter⁷,Brucker Sara⁶,Henes Melanie⁶,Sasieni Peter³⁴

Affiliation:

1. Institute of Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany

2. Frauenärzte am Staden, Saarbrücken, Germany

3. Centre for Cancer Prevention, Queen Mary University of London, London, United Kingdom

4. Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom

5. Department of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany

6. Department of Gynaecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany

7. Medical Faculty Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Tübingen, Germany

Abstract

Longitudinal data on the E6/E7 mRNA-based Aptima human papillomavirus (AHPV) assay exceeding three years in comparison to the gold standard Digene Hybrid Capture 2 (HC2) test are not available. We previously reported the cross-sectional data of the German AHPV Screening Trial (GAST) in which 10,040 women were recruited and tested by liquid-based cytology, the HC2 assay, and the AHPV assay.

Funder

Cancer Research UK

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01177-18

Reference32 articles.

1. Biological agents. Volume 100 B. A review of human carcinogens;IARC Working Group on the Evaluation of Carcinogenic Risks to Humans;IARC Monogr Eval Carcinog Risks Hum,2012

2. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

3. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial

4. Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer

5. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control;Viruses;2024-08-25

2. RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9‐year follow‐up;Cancer Cytopathology;2024-08-19

3. Special RCA based sensitive point‐of‐care detection of HPV mRNA for cervical cancer screening;Aggregate;2024-05-13

4. Analysis of the application value of HPV mRNA and DNA detection in early screening of cervical lesions;Future Virology;2024-03-03

5. Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland;International Journal of Cancer;2023-08-26